History & Mission

Corona Antibody Team

CORAT Therapeutics GmbH is a clinical phase biopharmaceutical company dedicated to develop therapeutic products to fight SARS-CoV-2 mediated COVID-19.

CORAT was founded as a spin off from the recombinant antibody development company Yumab GmbH. It´s most advanced clinical product, the antibody COR-101, was discovered in the lab of Prof. Dr. Stefan Dübel and Prof. Dr. Michael Hust at the Braunschweig University of Technology.

CORAT is located in Braunschweig (Germany) and is co-funded by the Lower Saxony State NBank and private investors. The company has successfully completed three financing rounds enabling to achieve e.g. completion of clinical trials and the preparation of commercial manufacturing processes.